TCRX · Insider Trading
TScan Therapeutics, Inc. Common Stock
Every open-market purchase and sale reported by TCRX officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-10-02 | Gavin MacBeath | Chief Executive Officer | A | +1,000,000 | — |
| 2026-10-02 | Zoran Zdraveski | See Remarks | A | +300,000 | — |
| 2026-05-22 | Katina Dorton | Director | A | +67,000 deriv. | — |
| 2026-05-22 | Garry A Nicholson | Director | A | +67,000 deriv. | — |
| 2026-05-22 | Gabriela Gruia | Director | A | +67,000 deriv. | — |
| 2026-05-22 | Barbara Klencke | Director | A | +67,000 deriv. | — |
| 2026-05-22 | Keith Woods | Director | A | +67,000 deriv. | — |
| 2026-05-22 | 667, L.P. | Director | A | +804,000 deriv. | — |
| 2026-01-22 | Gavin MacBeath | Chief Executive Officer | A | +1,165,000 deriv. | — |
| 2026-01-22 | Chrystal Louis | Chief Medical Officer | A | +420,000 deriv. | — |
| 2026-01-22 | Jason Amello | Chief Financial Officer | A | +350,000 deriv. | — |
| 2026-01-22 | Zoran Zdraveski | See Remarks | A | +350,000 deriv. | — |
| 2026-01-22 | Leiden Dworak | See Remarks | A | +100,000 deriv. | — |
| 2025-12-23 | Weston Nichols | 10%+ Owner | Buy | +323,602 | +$291.05K |
| 2025-07-02 | Gabriela Gruia | Director | A | +67,000 deriv. | — |
| 2025-07-02 | Katina Dorton | Director | A | +67,000 deriv. | — |
| 2025-07-02 | 667, L.P. | Director | A | +804,000 deriv. | — |
| 2025-07-02 | Garry A Nicholson | Director | A | +67,000 deriv. | — |
| 2025-07-02 | Keith Woods | Director | A | +67,000 deriv. | — |
| 2025-07-02 | Barbara Klencke | Director | A | +67,000 deriv. | — |
| 2025-05-21 | Lynx1 Capital Management LP | 10%+ Owner | Buy | +5,177,588 | +$6.21M |
| 2025-02-11 | Gavin MacBeath | Chief Executive Officer | A | +960,000 deriv. | — |
| 2025-02-11 | Leiden Dworak | — | A | +46,875 deriv. | — |
| 2025-02-11 | Jason Amello | Chief Financial Officer | A | +270,000 deriv. | — |
| 2025-02-11 | Chrystal Louis | Chief Medical Officer | A | +400,000 deriv. | — |
| 2025-02-11 | Zoran Zdraveski | See Remarks | A | +302,500 deriv. | — |
| 2024-12-30 | Lynx1 Capital Management LP | 10%+ Owner | Buy | +15,000,000 deriv. | — |
| 2024-12-16 | Lynx1 Capital Management LP | 10%+ Owner | Buy | +263,600 | +$771.54K |
| 2024-11-19 | Lynx1 Capital Management LP | 10%+ Owner | Buy | +1,894 | +$8.23K |
| 2024-09-24 | Barbara Klencke | Director | Buy | +5,000 | +$26.45K |
| 2024-08-27 | Zoran Zdraveski | See Remarks | MIXED | −7,500 | −$420.60K |
| 2024-08-27 | Barbara Klencke | Director | Buy | +10,000 | +$56.10K |
| 2024-06-14 | Keith Woods | Director | A | +47,500 deriv. | — |
| 2024-06-14 | Katina Dorton | Director | A | +47,500 deriv. | — |
| 2024-06-14 | Gabriela Gruia | Director | A | +47,500 deriv. | — |
| 2024-06-14 | Garry A Nicholson | Director | A | +71,250 deriv. | — |
| 2024-06-14 | 667, L.P. | Director | A | +570,000 deriv. | — |
| 2024-06-14 | Barbara Klencke | Director | A | +47,500 deriv. | — |
| 2024-05-03 | Chrystal Louis | Chief Medical Officer | A | +380,000 deriv. | — |
| 2024-04-23 | Lynx1 Capital Management LP | 10%+ Owner | Buy | +10,000,000 deriv. | — |
| 2024-04-23 | Baker Brothers Life Sciences LP | Director | Buy | +58,064,514 deriv. | — |
| 2024-02-02 | Jason Amello | Chief Financial Officer | A | +750,000 deriv. | — |
| 2023-12-21 | Timothy J Barberich | Director | Buy | +29,147 | +$142.46K |
| 2023-12-18 | Barbara Klencke | Director | Buy | +5,000 | +$25.40K |
| 2023-12-08 | Keith Woods | Director | A | +17,500 deriv. | — |
| 2023-07-24 | Leiden Dworak | Chief Accounting Officer | A | +25,000 deriv. | — |
| 2023-06-15 | Gavin MacBeath | Chief Executive Officer | A | +1,121,300 deriv. | — |
| 2023-06-15 | Brian M. Silver | Chief Financial Officer | A | +632,500 deriv. | — |
| 2023-06-15 | Katina Dorton | Director | A | +35,000 deriv. | — |
| 2023-06-15 | Zoran Zdraveski | Chief Legal Officer | A | +430,000 deriv. | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Weston Nichols | 10%+ Owner | 8,019,148 | $1.52M |
| Lynx1 Capital Management LP | 10%+ Owner | 6,746,141 | $1.28M |
| Gavin MacBeath | Chief Executive Officer | 1,049,767 | $199.14K |
| Zoran Zdraveski | See Remarks | 304,716 | $57.80K |
| Barbara Klencke | Director | 70,000 | $13.28K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the TCRX quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.